Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage with an 'Outperform' rating and a price target of $4.

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...

Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...

Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as ...

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...

Context Therapeutics has a one year low of $0.89 and a one year high of $2.75. The company has a market cap of $81.00 million, a P/E ratio of -1.19 and a beta of 2.10.

JMP Securities initiated coverage of Context Therapeutics (CNTX) with an Outperform rating and $4 price target Context is a $97.8M market cap clinical-stage biotechnology company focused on ...

Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule ...

PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...